A real-world pharmacovigilance study of fda adverse event reporting system (faers) events for niraparib

HIGHLIGHTS

• who: Menglin Guo from the DepartmentHuazhong University have published the article: A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib, in the Journal: Scientific Reports Scientific Reports
• what: The authors evaluated the AE reports of niraparib, and aimed to assess the potential relevance between niraparib and AE reports through data mining of FAERS. Myelosuppression were the main reason for discontinuation but were relatively infrequent, and the niraparib package insert advises checking complete blood counts periodically.
• how: As shown in Fig 1 results indicated that the onsets of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.